Base de dados : MEDLINE
Pesquisa : E02.319.267.120.060 [Categoria DeCS]
Referências encontradas : 18008 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1801 ir para página                         

  1 / 18008 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480848
[Au] Autor:Yammine L; Kosten TR; Cinciripini PM; Green CE; Meininger JC; Minnix JA; Newton TF
[Ad] Endereço:University of Texas Health Science Center at Houston.
[Ti] Título:Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial.
[So] Source:Medicine (Baltimore);97(2):e9567, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cigarette smoking is the greatest preventable cause of morbidity and premature mortality in the United States. Approved pharmacological treatments for smoking cessation are marginally effective, underscoring the need for improved pharmacotherapies. A novel approach might use glucagon-like peptide-1 (GLP-1) agonists, which reduce alcohol and drug use in preclinical studies. GLP-1 is produced in the intestinal L-cells and in the hindbrain. The peptide maintains glucose homeostasis and reduces food intake. Several GLP-1 agonists are used clinically to treat type 2 diabetes and obesity, but none have been tested in humans to reduce smoking. AIMS: We will examine whether extended-release exenatide reduces smoking, craving, and withdrawal symptoms, as well as cue-induced craving for cigarettes. METHODS: We will enroll prediabetic and/or overweight treatment seeking smokers (n = 90) into a double-blind, placebo-controlled, randomized clinical trial. Participants will be randomized in a 1:1 ratio to receive exenatide or placebo. All participants will receive transdermal nicotine replacement therapy (NRT) and behavioral counseling. Abstinence from smoking (verified via expired CO level of ≤5 ppm), craving (Questionnaire of Smoking Urges score), and withdrawal symptoms (Wisconsin Scale of Withdrawal Symptoms score) will be assessed weekly during 6 weeks of treatment and at 1 and 4 weeks posttreatment. Cue-induced craving for cigarettes will be assessed at baseline and at 3 weeks of treatment following virtual reality exposure. EXPECTED OUTCOMES: We hypothesize that exenatide will increase the number of participants able to achieve complete smoking abstinence above that achieved via standard NRT and that exenatide will reduce craving and withdrawal symptoms, as well as cue-induced craving for cigarettes.
[Mh] Termos MeSH primário: Peptídeo 1 Semelhante ao Glucagon/agonistas
Peptídeos/administração & dosagem
Abandono do Hábito de Fumar
Fumar/tratamento farmacológico
Peçonhas/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Adolescente
Adulto
Idoso
Aconselhamento
Fissura/efeitos dos fármacos
Preparações de Ação Retardada
Método Duplo-Cego
Esquema de Medicação
Seres Humanos
Meia-Idade
Abandono do Hábito de Fumar/métodos
Síndrome de Abstinência a Substâncias/tratamento farmacológico
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Peptides); 0 (Venoms); 89750-14-1 (Glucagon-Like Peptide 1); 9P1872D4OL (exenatide)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009567


  2 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457645
[Au] Autor:Maggini I; Kennedy LV; Bursian SJ; Dean KM; Gerson AR; Harr KE; Link JE; Pritsos CA; Pritsos KL; Guglielmo CG
[Ad] Endereço:Advanced Facility for Avian Research, University of Western Ontario, London, ON, Canada N6G 1G9; Konrad-Lorenz Institute of Ethology, University of Veterinary Medicine, Savoyenstrasse 1a, 1160 Vienna, Austria. Electronic address: ivan.maggini@vetmeduni.ac.at.
[Ti] Título:Toxicological and thermoregulatory effects of feather contamination with artificially weathered MC 252 oil in western sandpipers (Calidris mauri).
[So] Source:Ecotoxicol Environ Saf;146:118-128, 2017 Dec.
[Is] ISSN:1090-2414
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The external contamination of bird feathers with crude oil might have effects on feather structure and thus on thermoregulation. We tested the thermoregulatory ability of western sandpipers (Calidris mauri) in a respirometry chamber with oil applied either immediately prior, or three days before the experiment. The birds were then exposed to a sliding cold temperature challenge between 27°C and -3°C to calculate thermal conductance. After the experiment, a large blood sample was taken and the liver extracted to measure a range of parameters linked to toxicology and oxidative stress. No differences in thermal conductance were observed among groups, but birds exposed to oil for three days had reduced body temperatures and lost more body mass during that period. At necropsy, oiled birds showed a decrease in plasma albumin and sodium, and an increase in urea. This is reflective of dysfunction in the kidney at the loop of Henle. Birds, especially when exposed to the oil for three days, showed signs of oxidative stress and oxidative damage. These results show that the ingestion of externally applied oil through preening or drinking can cause toxic effects even in low doses, while we did not detect a direct effect of the external oil on thermoregulation over the temperature range tested.
[Mh] Termos MeSH primário: Regulação da Temperatura Corporal/efeitos dos fármacos
Charadriiformes/fisiologia
Plumas/química
Estresse Oxidativo/efeitos dos fármacos
Petróleo/toxicidade
Poluentes Químicos da Água/toxicidade
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Peso Corporal/efeitos dos fármacos
Charadriiformes/sangue
Metabolismo Energético/efeitos dos fármacos
Fígado/efeitos dos fármacos
Fígado/metabolismo
Poluição por Petróleo/efeitos adversos
Testes de Toxicidade
Tempo (Meteorologia)
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Petroleum); 0 (Water Pollutants, Chemical)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  3 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779568
[Au] Autor:Santoro N; Allshouse A; Neal-Perry G; Pal L; Lobo RA; Naftolin F; Black DM; Brinton EA; Budoff MJ; Cedars MI; Dowling NM; Dunn M; Gleason CE; Hodis HN; Isaac B; Magnani M; Manson JE; Miller VM; Taylor HS; Wharton W; Wolff E; Zepeda V; Harman SM
[Ad] Endereço:1Department of Obstetrics & Gynecology 2Department of Biostatistics, University of Colorado School of Medicine, Aurora, CO 3Department of Obstetrics, Gynecology & Women's Health and Neurosciences, Albert Einstein College of Medicine, Bronx, NY 4Department of Obstetrics & Gynecology, Yale University School of Medicine, New Haven, CT 5Department of Obstetrics & Gynecology, Columbia University College of Physicians and Surgeons, New York, NY 6Department of Obstetrics & Gynecology, New York University School of Medicine, New York, NY 7Department of Epidemiology & Biostatistics, University of California at San Francisco, San Francisco, CA 8Utah Foundation for Biomedical Research, Salt Lake City, UT 9Department of Cardiology, Los Angeles Biomedical Research Institute at Harbor UCLA, Torrance, CA 10Department of Obstetrics & Gynecology, University of California at San Francisco, San Francisco, CA 11Departments of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI 12Kronos Longevity Research Institute, Phoenix, AZ 13Department of Medicine and Public Health, University of Wisconsin, Madison, WI 14Atherosclerosis Research Unit, University of Southern California, Los Angeles, CA 15Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 16Departments of Surgery and Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN 17Department of Neurology, Emory University, Atlanta, GA 18Department of Reproductive Biology and Medicine, National Institutes of Health, Bethesda, MD 19Department of Medicine, Endocrine Division, Phoenix VA Health Care System, Phoenix, AZ.
[Ti] Título:Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study.
[So] Source:Menopause;24(3):238-246, 2017 Mar.
[Is] ISSN:1530-0374
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: The objective of the present study was to compare the efficacy of two forms of menopausal hormone therapy in alleviating vasomotor symptoms, insomnia, and irritability in early postmenopausal women during 4 years. METHODS: A total of 727 women, aged 42 to 58, within 3 years of their final menstrual period, were randomized to receive oral conjugated estrogens (o-CEE) 0.45 mg (n = 230) or transdermal estradiol (t-E2) 50 µg (n = 225; both with micronized progesterone 200 mg for 12 d each mo), or placebos (PBOs; n = 275). Menopausal symptoms were recorded at screening and at 6, 12, 24, 36, and 48 months postrandomization. Differences in proportions of women with symptoms at baseline and at each follow-up time point were compared by treatment arm using exact χ tests in an intent-to-treat analysis. Differences in treatment effect by race/ethnicity and body mass index were tested using generalized linear mixed effects modeling. RESULTS: Moderate to severe hot flashes (from 44% at baseline to 28.3% for PBO, 7.4% for t-E2, and 4.2% for o-CEE) and night sweats (from 35% at baseline to 19% for PBO, 5.3% for t-E2, and 4.7% for o-CEE) were reduced significantly by 6 months in women randomized to either active hormone compared with PBO (P < 0.001 for both symptoms), with no significant differences between the active treatment arms. Insomnia and irritability decreased from baseline to 6 months postrandomization in all groups. There was an intermittent reduction in insomnia in both active treatment arms versus PBO, with o-CEE being more effective than PBO at 36 and 48 months (P = 0.002 and 0.05) and t-E2 being more effective than PBO at 48 months (P = 0.004). Neither hormone treatment significantly affected irritability compared with PBO. Symptom relief for active treatment versus PBO was not significantly modified by body mass index or race/ethnicity. CONCLUSIONS: Recently postmenopausal women had similar and substantial reductions in hot flashes and night sweats with lower-than-conventional doses of oral or transdermal estrogen. These reductions were sustained during 4 years. Insomnia was intermittently reduced compared with PBO for both hormone regimens.
[Mh] Termos MeSH primário: Estrogênios/administração & dosagem
Fogachos/tratamento farmacológico
Humor Irritável/efeitos dos fármacos
Progestinas/administração & dosagem
Distúrbios do Início e da Manutenção do Sono/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Adulto
Doenças do Sistema Nervoso Autônomo/tratamento farmacológico
Doenças do Sistema Nervoso Autônomo/etiologia
Quimioterapia Combinada
Estradiol/administração & dosagem
Terapia de Reposição de Estrogênios/métodos
Estrogênios Conjugados (USP)/administração & dosagem
Feminino
Fogachos/etiologia
Seres Humanos
Estudos Longitudinais
Meia-Idade
Pós-Menopausa/efeitos dos fármacos
Progesterona/administração & dosagem
Distúrbios do Início e da Manutenção do Sono/etiologia
Resultado do Tratamento
Sistema Vasomotor/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Estrogens); 0 (Estrogens, Conjugated (USP)); 0 (Progestins); 4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1097/GME.0000000000000756


  4 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220342
[Au] Autor:Trimble JO; Light B
[Ad] Endereço:Humco Compounding, Austin, Texas.
[Ti] Título:Effect of Penetration Enhancers on the Percuaneous Delivery of Hormone Replacement Actives.
[So] Source:Int J Pharm Compd;21(6):530-535, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Transdermal compositions for hormone replacement are comprised of exogenous hormones that are biochemically similar to those produced endogenously by the ovaries or elsewhere in the body. In this work, estradiol, estriol, and testosterone were loaded in transdermal vehicles, prepared using one of three selected penetration enhancer mixtures: Vehicle 1 (olive oil and oleic acid), Vehicle 2 (isopropyl palmitate and lecithin), and Vehicle 3 (isopropyl myristate and lecithin). The influence of penetration enhancers on transdermal delivery was evaluated using Franz-type diffusion cells and Normal Human 3D Model of Epidermal Tissue. Results showed that drug delivery is affected by the penetration enhancer used in the transdermal composition.
[Mh] Termos MeSH primário: Terapia de Reposição Hormonal
Absorção Cutânea
[Mh] Termos MeSH secundário: Administração Cutânea
Cromatografia Líquida de Alta Pressão
Estradiol/administração & dosagem
Estradiol/química
Estradiol/farmacocinética
Seres Humanos
Permeabilidade
Solubilidade
Testosterona/administração & dosagem
Testosterona/química
Testosterona/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
3XMK78S47O (Testosterone); 4TI98Z838E (Estradiol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  5 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220333
[Au] Autor:Forsythe LE
[Ad] Endereço:Veterinary Medical Teaching Hospital, University of California-Davis, Davis, California. leichstadt@ucdavis.edu.
[Ti] Título:Feline Transdermal Formulation Considerations.
[So] Source:Int J Pharm Compd;21(6):446-452, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Transdermal delivery of drugs is comparatively new in feline patients. However, transdermal formulations can be a desirable option for treating feline patients that are not willing participants to medication administration. However, achieving drug penetration across the skin is not always easy, and there are a wide variety of variables that can further affect penetration. This, coupled with a lack of studies, make transdermal administration an unknown with regards to efficacy and safety for many drugs. This article focuses on drugs that are administered transdermally with the intent of producing systemic effects.
[Mh] Termos MeSH primário: Doenças do Gato/tratamento farmacológico
Drogas Veterinárias/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Animais
Gatos
Química Farmacêutica
Descoberta de Drogas
Pele/anatomia & histologia
Absorção Cutânea
Drogas Veterinárias/química
Drogas Veterinárias/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Veterinary Drugs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  6 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29394018
[Au] Autor:Yuanxi L; Wei H; Lidan X; Li L
[Ti] Título:Comparison of skin hydration in combination and single use of common moisturizers (cream, toner, and spray water).
[So] Source:J Cosmet Sci;67(3):175-83, 2016 May-Jun.
[Is] ISSN:1525-7886
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study aims to assess the moisturization in combination or single use (including seven general applications) of three common moisturizers: cream, toner, and spray water. Groups were set as C: cream only; T: toner only; C+T, T+C: cream or toner applied successively within a few minutes; C-T, C-S: cream applied with repeated toner or spray water every 2 h; T-T: toner applied with repeated toner every 2 h; and N: untreated group. Outcomes were the change in skin hydration from baseline at 2, 4, 6, and 8 h after applications. All treated zones displayed a significantly higher degree of hydration compared with the untreated zone ( p < 0.05). For normal skin (hydration value at baseline >35 a.u.), C-T led to greatest hydration change rate compared with others, followed by C+T, T+C, and C. Those three applications exhibited analogous hydration at each test point ( p > 0.05). The hydration rate of C-S differed slightly from T-T, followed by those four mentioned above, with T being the last. For dry skin (hydration value at baseline <35 a.u.), no statistical significance could be detected between C-T zone and C+T, T+C, and C zones ( p > 0.05), the other results were identical. When cream and toner were applied successively, the application order has little effect on skin hydration. The application of cream only was an effective and brief way to achieve favorable moisturization especially for dry skin. As a complement, repeated application of toner rather than spray water is efficacious for skin hydration.
[Mh] Termos MeSH primário: Emolientes/uso terapêutico
Dermatopatias/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Emolientes/administração & dosagem
Emolientes/farmacologia
Feminino
Seres Humanos
Dermatopatias/fisiopatologia
Fenômenos Fisiológicos da Pele
Perda Insensível de Água
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Emollients)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE


  7 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29394016
[Au] Autor:Nualsri C; Lourith N; Kanlayavattanakul M
[Ti] Título:Development and clinical evaluation of green tea hair tonic for greasy scalp treatment.
[So] Source:J Cosmet Sci;67(3):161-66, 2016 May-Jun.
[Is] ISSN:1525-7886
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Green tea has cosmetic benefits that include activities against androgen disorders. A hair tonic containing green tea for reduction of scalp sebum was developed and clinically evaluated. Stable green tea hair tonics were closed-patch tested and clinically evaluated in 20 volunteers for 28 days by using a Sebumeter ® . Hair tonic base with glycerin and butylene glycol (total 4%) gained the highest consumers' preference was incorporated with green tea extract. All of the products were stable and none caused skin irritation. Green tea hair tonic (2%) significantly (p ≤ 0.024) lowered scalp sebum for 21 and 28 days following the application, suggesting that this topical therapy of scalp greasiness is safe and efficient.
[Mh] Termos MeSH primário: Preparações para Cabelo/uso terapêutico
Extratos Vegetais/uso terapêutico
Dermatoses do Couro Cabeludo/tratamento farmacológico
Sebo/efeitos dos fármacos
Chá
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Feminino
Preparações para Cabelo/farmacologia
Seres Humanos
Masculino
Testes do Emplastro
Extratos Vegetais/farmacologia
Valores de Referência
Sebo/secreção
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hair Preparations); 0 (Plant Extracts); 0 (Tea)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE


  8 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29195486
[Au] Autor:Shukla S; Feldman SR; Strowd LC
[Ad] Endereço:a University of Maryland School of Medicine , Baltimore , MD , USA.
[Ti] Título:A safety review of the medications used to treat atopic dermatitis.
[So] Source:Expert Opin Drug Saf;17(2):179-183, 2018 Feb.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Atopic dermatitis (AD) is a common disease in children and adults which causes severe physical discomfort and psychosocial distress. Recently novel therapies for AD have been FDA approved for use which creates the need to review the safety surrounding current FDA approved AD medications. Areas covered: Published clinical studies involving topical and oral FDA approved medications for AD are included in this review. Authors used PubMed research database to search for clinical trials involving AD patients. Expert opinion: AD is a common disease which currently has limited FDA approved medications. Given the chronicity of this disease, medications are needed which control disease while minimizing side effects to allow for long term use. Newer approved medications show promise but safety data is limited given their relatively new utilization for AD.
[Mh] Termos MeSH primário: Dermatite Atópica/tratamento farmacológico
Fármacos Dermatológicos/administração & dosagem
[Mh] Termos MeSH secundário: Administração Cutânea
Administração Oral
Adulto
Criança
Dermatite Atópica/patologia
Fármacos Dermatológicos/efeitos adversos
Aprovação de Drogas
Seres Humanos
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Dermatologic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171203
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2018.1411478


  9 / 18008 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29328637
[Au] Autor:Filipovic M; Gledovic A; Lukic M; Tasic-Kostov M; Isailovic T; Pantelic I; Vuleta G; Savic S
[Ti] Título:Alp Rose stem cells, olive oil squalene and a natural alkyl polyglucoside emulsifier: Are they appropriate ingredients of skin moisturizers - in vivo efficacy on normal and sodium lauryl sulfate - irritated skin?.
[So] Source:Vojnosanit Pregl;73(11):991-1002, 2016 11.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Ab] Resumo:Background/Aim: Since skin moisturization may be achieved by both actives and chosen carrier, plant stem cells, squalene and natural alkyl polyglucoside emulsifier may be potential components of contemporary cosmetic products. The aim of the study was in vivo evaluation of the skin irritation potential and the efficacy of Alpine Rose stem cells incorporated into li-posomes and olive oil squalene as ingredients of moisturizing creams, with respect to the novel emulsifier used for creams' stabilization. Methods: With the employment of noninvasive skin biophysical measurements, skin hydration (EC), transepi-dermal water loss (TEWL), erythema index (EI) and viscoelas-ticity were measured on 76 healthy volunteers. In the first phase, skin irritation after a 24-hour occlusion and the long-term efficacy of creams (a 21-day study) on healthy skin were evaluated. Phase II of the study focused on the cream efficacy assessment after a 6-day treatment of sodium lauryl sulfate-irritated skin. Results: After a 24-hour occlusion, there were no significant changes in the EI for any tested sample. In the second phase of the study, the EI was not significantly altered for the cream containing squalene, while the application of all active samples resulted in a significant reduction of TEWL. In both phases of the study an EC increase was recorded, espe-cially for the squalene-containing cream. Conclusion: Due to the lack of skin irritation and skin barrier impairment along with the marked hydration effect, it could be said that the in-vestigated actives incorporated into alkyl polyglucoside emulsi-fier-stabilized creams may be safely applied as ingredients for "tailor-made" cosmetic moisturizers intended for normal and dry skin care, whereas olive oil squalene could be used for the treatment of irritated or sensitive skin as well. [Projekat Ministarstva nauke Republike Srbije, br. TR34031]
[Mh] Termos MeSH primário: Emulsificantes/administração & dosagem
Glucosídeos/administração & dosagem
Azeite de Oliva/química
Rhododendron/citologia
Creme para a Pele/administração & dosagem
Testes de Irritação da Pele/métodos
Pele/efeitos dos fármacos
Dodecilsulfato de Sódio/toxicidade
Esqualeno/administração & dosagem
Células-Tronco/fisiologia
[Mh] Termos MeSH secundário: Administração Cutânea
Adulto
Segurança de Produtos ao Consumidor
Método Duplo-Cego
Elasticidade
Emulsificantes/efeitos adversos
Feminino
Glucosídeos/efeitos adversos
Seres Humanos
Lipossomos
Fitoterapia
Plantas Medicinais
Medição de Risco
Sérvia
Pele/metabolismo
Pele/patologia
Creme para a Pele/efeitos adversos
Esqualeno/efeitos adversos
Esqualeno/isolamento & purificação
Fatores de Tempo
Viscosidade
Perda Insensível de Água/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Emulsifying Agents); 0 (Glucosides); 0 (Liposomes); 0 (Olive Oil); 368GB5141J (Sodium Dodecyl Sulfate); 7QWM220FJH (Squalene)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150116122F


  10 / 18008 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337676
[Au] Autor:Pajic NZB; Todosijevic MN; Vuleta GM; Cekic ND; Dobricic VD; Vucen SR; Calija BR; Lukic MZ; Ilic TM; Savic SD
[Ad] Endereço:1Department of Pharmaceutical Technology and Cosmetology Faculty of Medicine, University of Banja Luka, 78000 Banja Luka Bosnia and Herzegovina.
[Ti] Título:Alkyl polyglucoside vs. ethoxylated surfactant-based microemulsions as vehicles for two poorly water-soluble drugs: physicochemical characterization and in vivo skin performance.
[So] Source:Acta Pharm;67(4):415-439, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Two types of biocompatible surfactants were evaluated for their capability to formulate skin-friendly/non-irritant microemulsions as vehicles for two poorly water-soluble model drugs differing in properties and concentrations: alkyl polyglucosides (decyl glucoside and caprylyl/capryl glucoside) and ethoxylated surfactants (glycereth-7-caprylate/ caprate and polysorbate 80). Phase behavior, structural inversion and microemulsion solubilization potential for sertaconazole nitrate and adapalene were found to be highly dependent on the surfactants structure and HLB value. Performed characterization (polarized light microscopy, pH, electrical conductivity, rheological, FTIR and DSC measurements) indicated a formulation containing glycereth- 7-caprylate/caprate as suitable for incorporation of both drugs, whereas alkyl polyglucoside-based systems did not exhibit satisfying solubilization capacity for sertaconazole nitrate. Further, monitored parameters were strongly affected by sertaconazole nitrate incorporation, while they remained almost unchanged in adapalene-loaded vehicles. In addition, results of the in vivo skin performance study supported acceptable tolerability for all investigated formulations, suggesting selected microemulsions as promising carriers worth exploring further for effective skin delivery of model drugs.
[Mh] Termos MeSH primário: Caprilatos/farmacocinética
Emulsões/farmacologia
Glucosídeos/farmacologia
Veículos Farmacêuticos/farmacocinética
Polissorbatos/farmacologia
Pele/metabolismo
Tensoativos/farmacologia
[Mh] Termos MeSH secundário: Adapaleno/farmacologia
Administração Cutânea
Adulto
Caprilatos/química
Emulsões/química
Glucosídeos/química
Seres Humanos
Imidazóis/farmacologia
Microscopia de Polarização
Veículos Farmacêuticos/química
Polissorbatos/química
Pele/efeitos dos fármacos
Testes de Irritação da Pele
Solubilidade
Espectroscopia de Infravermelho com Transformada de Fourier
Tensoativos/química
Tiofenos/farmacologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Caprylates); 0 (Emulsions); 0 (Glucosides); 0 (Imidazoles); 0 (Pharmaceutical Vehicles); 0 (Polysorbates); 0 (Surface-Active Agents); 0 (Thiophenes); 1L4806J2QF (Adapalene); 72W71I16EG (sertaconazole); Z17H97EA6Y (decyl glucoside)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE



página 1 de 1801 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde